ABSTRACT
Abstract: Optic Neuritis (ON) is a condition caused by the inflammation of the optic nerve, causing diminished visual acuity and ocular pain. It is tightly related to Multiple Sclerosis (MS), often being the first demyelinating event. There is a 31% risk of recurrence during the first 10 years after the diagnosis, and 48% of the patients end up being diagnosed with Multiple Sclerosis1. Imaging studies like brain MRI (Magnetic Resonance Imaging) have a critical role in the diagnosis and prognosis of ON, as well as in the recognition of MS.2 The patient is a 11-year-old girl with recurrent ON and past medical history of Acute Disseminated Encephalomyelitis (ADEM) when she was 5 years old. ON diagnosis was based on clinical findings as well as on ophtalmologic, electrophysiologic and imaging studies. The recurrent episodes of ON improved after the use of high dose steroids. Recurrences were observed after titration of the dose, but remission was achieved after adjustment of treatment. During one of the recurrent episodes, blood work was performed to evaluate possible underlying infectious, demyelinating or autoinmmune process. Anti-MOG antibodies were found positive. The patient at the moment is not presenting with any other criteria suggesting MS or Optic Neuromyelitis, but long term follow up is adviced. Key words: Optic neuritis (ON), multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), right eye (RE); visual acuity (VA), optic neuromyelitis (ONM)
Subject(s)
Humans , Optic Neuritis , Encephalomyelitis, Acute Disseminated , Magnetic Resonance Imaging , Cerebrospinal Fluid , Antibodies , Multiple SclerosisABSTRACT
Es sabida la acción terapéutica favorable que los bifosfonatos ocasionan en el tejido óseo en aquellos pacientes que presentan como causa etiológica la osteoporosis. El presente artículo pretende relacionar tratamientocrónico con bifosfonatos nitrogenados y la cirugía oral, para lo cual la AAOMS define el concepto de Osteonecrosis Maxilar (ONM) asociada a tratamientocrónico con bifosfonatos como: Área ósea necrótica expuesta al medio bucal con más de ocho semanas de permanencia, en presencia de tratamiento crónico con bifosfonatos en ausencia de radioterapia en cabeza ycuello
It is known the correct therapeutic actions that Bisphosphonates involved in bone tissue when patientsare affected with a pathologic cause: Osteoporosis.This article is supposed to communicate the interaction between nitrogen bisphosphonates and oral surgery, for that reason AAOMS describes Osteonecrosisof the Jaw (ONJ) as: Exposed, necrotic bone in the maxillofacial region that has persisted for more than eight weeks with current or pervious treatment with bisphosphonates and had no history of radiation to thejaw.
Subject(s)
Humans , Diphosphonates/adverse effects , Jaw Diseases/prevention & control , Osteonecrosis/etiology , Surgery, Oral , Jaw Diseases/etiology , Bone Diseases/drug therapy , Osteonecrosis/prevention & control , Osteoporosis/drug therapyABSTRACT
Es sabida la acción terapéutica favorable que los bifosfonatos ocasionan en el tejido óseo en aquellos pacientes que presentan como causa etiológica la osteoporosis. El presente artículo pretende relacionar tratamientocrónico con bifosfonatos nitrogenados y la cirugía oral, para lo cual la AAOMS define el concepto de Osteonecrosis Maxilar (ONM) asociada a tratamientocrónico con bifosfonatos como: Area ósea necrótica expuesta al medio bucal con más de ocho semanas de permanencia, en presencia de tratamiento crónico con bifosfonatos en ausencia de radioterapia en cabeza ycuello (AU)
It is known the correct therapeutic actions that Bisphosphonates involved in bone tissue when patientsare affected with a pathologic cause: Osteoporosis.This article is supposed to communicate the interaction between nitrogen bisphosphonates and oral surgery, for that reason AAOMS describes Osteonecrosisof the Jaw (ONJ) as: ôExposed, necrotic bone in the maxillofacial region that has persisted for more than eight weeks with current or pervious treatment with bisphosphonates and had no history of radiation to thejawö.(AU)
Subject(s)
Humans , Osteonecrosis/etiology , Diphosphonates/adverse effects , Jaw Diseases/prevention & control , Surgery, Oral , Jaw Diseases/etiology , Bone Diseases/drug therapy , Osteoporosis/drug therapy , Osteonecrosis/prevention & controlABSTRACT
Los bifosfonatos presentan una acción terapéutica favorable en el tejido óseo de aquellos pacientes que presentan como causa etiológica la osteoporosis. El presente artículo pretende relacionar tratamiento crónico con bifosfonatos nitrogenados y osteoporosis, para lo cual la AAOMS define el concepto de osteonecrosis maxilar (ONM) asociada a tratamiento crónico con bifosfonatos como: área ósea necrótica expuesta al medio bucal con más de ocho semanas de permanencia, en presencia de tratamiento crónico con bifosfonatos, en ausencia de radioterapia en cabeza y cuello
Subject(s)
Humans , Diphosphonates/adverse effects , Jaw Diseases/etiology , Osteonecrosis/chemically induced , Osteoporosis/drug therapy , Chronic Disease , Osteonecrosis/etiologyABSTRACT
Los bifosfonatos presentan una acción terapéutica favorable en el tejido óseo de aquellos pacientes que presentan como causa etiológica la osteoporosis. El presente artículo pretende relacionar tratamiento crónico con bifosfonatos nitrogenados y osteoporosis, para lo cual la AAOMS define el concepto de osteonecrosis maxilar (ONM) asociada a tratamiento crónico con bifosfonatos como: área ósea necrótica expuesta al medio bucal con más de ocho semanas de permanencia, en presencia de tratamiento crónico con bifosfonatos, en ausencia de radioterapia en cabeza y cuello (AU)